Green Cash Money

Neoprobe Corporation, a biomedical company, develops and commercializes surgical and diagnostic products that enhance patient care by meeting the intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. The company primarily offers a line of gamma radiation detection equipment used in the application of sentinel lymph node biopsy (SLNB), and a line of blood flow monitoring devices for various diagnostic and surgical applications. Its products include neoprobe GDS gamma detection system; and Quantix/OR, which is designed to permit cardiovascular surgeons to obtain intraoperative volume blood flow readings in various targeted blood vessels within seconds. The company also holds developmental and/or intellectual property rights related to two drugs can be used in connection with gamma detection devices in cancer surgeries. Its drugs under development include Lymphoseek, which determines the spread of solid tumor cancers into the lymphatic system; and RIGScan CR that enables surgeons to locate cancerous or disease involved tissue during colorectal cancer surgeries. The company was founded in 1983 and is based in Dublin, Ohio.

NEOP at 9:56 AM 6/2/2009:  Crossed daily highs resistance.

Cambridge Heart, Inc. engages in the research, development, and commercialization of products for the non-invasive diagnosis of cardiac disease in the United States and internationally. Its products primarily include the Heartwave II System used to perform a Microvolt T-Wave Alternans Test, which requires an elevated heart rate to provide an accurate result; the Micro-V Alternans Sensors, which are single patient use, multi-segment electrodes that are required for the Microvolt T-Wave Alternans Test; and the CH 2000 Cardiac Stress Test System, a diagnostic system designed to support a range of standard and physician-customized protocols for the conduct and measurement of cardiac exercise stress tests. The company sells its products primarily to cardiology group practices, hospitals, and research institutions. Cambridge Heart markets its products internationally through independent distributors. The company was founded in 1990 and is based in Tewksbury, Massachusetts.

CAMH at 11:03 AM 4/9/2009:  Trading 25% above VWAP